Star will employ a hub-and-spoke model to launch portfolio companies focused on specific biological areas. The first company, Electra, will emphasize unmet medical needs and therapies that can address multiple diseases.

Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.

The deal bolsters Sanofi’s immuno-oncology pipeline and marks its sixth acquisition this year.

June, July and August brought a number of important new approvals and trial announcements from the major cardiac device companies. Here are some of the highlights you might have missed during the summer.